Hydrochloric Acid

Hydrochloric Acid

SCHEMBL460431

Cl.Cl.N=C(N)c1ccccc1-c1cc2c(C(=N)N)cccc2[nH]1

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
KLKB1 known ✓ P03952 7/20 0.52
HDAC11 known ✓ Q96DB2 1/20 0.35
PLAU P00749 12/20 0.52
PRSS1 P07477 12/20 0.52
PLAT P00750 11/20 0.52
F2 P00734 11/20 0.52
F10 P00742 10/20 0.52
PRSS2 P07478 9/20 0.52
PRSS3 P35030 9/20 0.52
F7 P08709 6/20 0.52
HPN P05981 4/20 0.44
PLG P00747 6/20 0.42
ST14 Q9Y5Y6 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6439094 1.00 PLAU (0.52) PLAUPRSS1PLATF2F10
SCHEMBL30478743 0.98 PLAU (0.53) PLAUPRSS1PLATF2F10
SCHEMBL1458860 0.98 PLAU (0.53) PLAUPRSS1PLATF2F10
Hydrochloric Acid SCHEMBL9057304 0.79 F2 (0.49) PLAUPRSS1PLATF2F10
SCHEMBL15271248 0.78 F2 (0.50) PLAUPRSS1PLATF2F10
SCHEMBL5073378 0.75 KDM4E (0.49) PLAUPRSS1PLATF2F10
Hydrochloric Acid SCHEMBL4551001 0.74 F2 (0.37) PLAUPRSS1PLATF2F10
SCHEMBL2874094 0.74 F2 (0.59) PLAUPRSS1PLATF2F10
SCHEMBL2864097 0.74 PLAU (0.52) PLAUPRSS1PLATF2F10
Hydrochloric Acid SCHEMBL6341904 0.72 BLM (0.50) PLAUPRSS1PLATF2F10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025127798-A1 STRONTIUM-EMITTING 3D PRINTING SCAFFOLD FOR PROMOTING BONE CARTILAGE REGENERATION AND METHOD FOR MANUFACTURING SAME 단국대학교 천안캠퍼스 산학협력단 2025-06-19 WO disclosed
EP-4346771-A1 NANOTECHNOLOGICAL PLATFORM BASED ON POLYURETHANE/POLYUREA CHEMISTRY TO FURNISH WATER-OIL-WATER MULTI WALLED AND FUNCTIONALIZABLE NANOCAPSULES AND THEIR PREPARATION PROCESS Ecopol Tech, S.L. (ES) 2024-04-10 EP disclosed
EP-4335433-A1 ORAL PHARMACEUTICAL COMPOSITION CONTAINING TERIPARATIDE FOR PREVENTION OR TREATMENT OF OSTEOPOROSIS AND PREPARATION METHOD THEREFOR Icure BNP Co., Ltd. (KR) 2024-03-13 EP disclosed
WO-2024038345-A1 COMPOUNDS USEFUL FOR THE TREATMENT AND/OR CARE OF THE SKIN, HAIR, NAILS AND/OR MUCOUS MEMBRANES LUBRIZOL ADVANCED MATERIALS, INC. (US) 2024-02-22 WO disclosed
US-20240041917-A1 TREATMENT FOR METHAMPHETAMINE CARDIOVASCULAR DISEASE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) 2024-02-08 US disclosed
US-11883426-B2 Treatment for methamphetamine cardiovascular disease BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) 2024-01-30 US disclosed
WO-2024019246-A1 ORAL PHARMACEUTICAL COMPOSITION CONTAINING TERIPARATIDE FOR PREVENTION OR TREATMENT OF OSTEOPOROSIS AND PREPARATION METHOD THEREFOR 주식회사 아이큐어비앤피 2024-01-25 WO disclosed
EP-4304582-A1 COMPOSITIONS AND METHODS FOR TREATING ADDICTIONS COMPRISING 5-MEO-DMT Alvarius Pharmaceuticals Ltd. (IE) 2024-01-17 EP disclosed
CN-117297993-A Composition for inducing growth of skin cells whose growth is inhibited by aging comprising flavonoids derived from camellia japonica 株式会社爱茉莉太平洋 2023-12-29 CN disclosed
US-20230392116-A1 METHOD FOR DIFFERENTIATING CORNEAL ENDOTHELIAL CELL-LIKE CELLS FROM PLURIPOTENT STEM CELLS STEMSIGHT OY (FI) 2023-12-07 US disclosed
US-6417223-B1 ANTIPROLIFERATION AGENTS OR APOTOPSIS RESEARCH DEVELOPMENT FOUNDATION 2002-07-09 US disclosed
US-6406843-B1 MICROORGANISM FOR USE IN VACCINATION AGAINST VIRAL DISEASES UNIVERSITY OF ARKANSAS 2002-06-18 US disclosed
EP-1203227-A1 SYSTEM AND METHOD FOR PRENATAL DIAGNOSTIC SCREENING BIOSEPARATIONS, INC. (US) 2002-05-08 EP disclosed
US-20020048806-A1 POULTRY VIRUS ISOLATES AND METHOD ARKANSAS, UNIVERSITY OF 2002-04-25 US disclosed
WO-2002026815-A2 IDENTIFICATION OF NEUROBLASTOMA TUMOR SUPPRESSOR GENES VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOLOGIE (BE) 2002-04-04 WO disclosed
US-6322792-B1 GAMMA-2 HERPES VIRUSES LIKE KAPOSI'S SARCOMA-ASSOCIATED HERPES VIRUS USEFUL IN MODULATING PERSISTENCE OF HETEROLOGOUS DNA; GENE THERAPY Kieff, Elliott D. 2001-11-27 US disclosed
US-20010029013-A1 Bcl-G polypeptides, encoding nucleic acids and methods of use BURNHAM INSTITUTE FOR MEDICAL RESEARCH 2001-10-11 US disclosed
WO-2000075647-A1 SYSTEM AND METHOD FOR PRENATAL DIAGNOSTIC SCREENING BIOSEPARATIONS, INC. (US) 2000-12-14 WO disclosed
EP-1019508-A1 TNF-RELATED DEATH LIGAND PHARMACIA & UPJOHN COMPANY (US) 2000-07-19 EP disclosed
WO-1999050416-A1 TNF-RELATED DEATH LIGAND PHARMACIA & UPJOHN COMPANY (US) 1999-10-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11883426-B2 Treatment for methamphetamine cardiovascular disease CBS, MPST, TST KLKB1 3114/4885HDAC11 1093/4885PLAU 3441/4885
US-20240041917-A1 TREATMENT FOR METHAMPHETAMINE CARDIOVASCULAR DISEASE STS, MPST, TST KLKB1 3708/4885HDAC11 789/4885PLAU 3105/4885
US-20020048806-A1 POULTRY VIRUS ISOLATES AND METHOD C9, ALPI, ACIN1 KLKB1 2861/4885HDAC11 2690/4885PLAU 3921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.